Precancerous skin lesions and malignant skin tumors associated with hydroxyurea treatment: Evaluation of a large series and review of the literature
Yıl: 2022 Cilt: 56 Sayı: 4 Sayfa Aralığı: 159 - 165 Metin Dili: İngilizce DOI: 10.4274/turkderm.galenos.2022.91489 İndeks Tarihi: 12-05-2023
Precancerous skin lesions and malignant skin tumors associated with hydroxyurea treatment: Evaluation of a large series and review of the literature
Öz: Background and Design: Malignant skin tumors have been reported in patients using hydroxyurea (HU) for hematological disorders. This study aimed to investigate the characteristics of precancerous skin lesions and malignant skin tumors in association with long-term HU therapy. Materials and Methods: Records of consecutive patients diagnosed with precancerous and cancerous skin lesions during HU therapy in a single dermatology department between 2008 and 2021 were retrospectively analyzed. Results: Among 13 patients (mean age: 66.5 years) treated with HU for five different hematological diseases, 11 had used HU >5 years, whereas the time was shorter in the other two patients. The period between HU treatment initiation and the appearance of the first lesion was approximately 9-10 years. Actinic keratosis (AKs) were found in two patients, non-melanoma skin cancers (NMSCs) accompanied by AKs in seven patients, and only NMSCs in four patients. Melanoma was seen in a patient with NMSCs and AKs. In total, 12 basal cell carcinomas (BCCs), 12 squamous cell carcinomas (SCCs), and one melanoma were diagnosed. The superficial type was the most common type of BCCs, followed by the nodular type. NMSCs were located mainly on the face, followed by the scalp, neck, and extensor surfaces of the upper extremities. Conclusion: The results of this large series support the possibility of the relationship between UV-induced skin cancer and HU therapy. SCCs and BCCs showed equal incidence in the present study in contrast to some previous reports, and different BCC types may occur in these patients. As many patients have more than one malignant skin tumor, protective measures against sunlight, which is another inducing factor for these tumors, and a long-term follow-up, should not be ignored.
Anahtar Kelime: Hidroksiüre tedavisi ile ilişkili prekanseröz deri lezyonları ve malign deri tümörleri: Geniş bir serinin değerlendirilmesi ve literatürün gözden geçirilmesi
Öz: Amaç: Hematolojik hastalıklar için hidroksiüre (HÜ) kullanan hastalarda malign deri tümörü gelişimi daha önce bildirilmiştir. Bu çalışma ile uzun süreli HÜ kullanımı ile ilişkili premalign deri lezyonları ve malign deri tümörlerinin tüm özelliklerinin araştırılması amaçlanmıştır. Gereç ve Yöntem: Tek bir dermatoloji merkezinde 2008-2021 yılları arasında HÜ tedavisi sırasında prekanseröz deri lezyonu veya malign deri tümörü tanısı alan ardışık hastaların dosyaları retrospektif olarak incelendi. Bulgular: Beş farklı hematolojik endikasyon için HÜ kullanan 13 hastada (ortalama yaş 66,5 yıl) prekanseröz deri lezyonu [aktinik keratoz (AK)] veya malign deri tümörü görüldü. Hastalardan 11’i bu ilacı 5 yıldan uzun süre kullanmışken 2’sinde bu süre daha kısaydı. İlk lezyonların oluşumu ile ilacın başlangıç tarihi arasında ortalama 9-10 yıllık bir süre vardı. İki hastada tek başına AK görülürken 7 hastada melanom dışı deri kanseri ve AK beraber görüldü. Dört hastada ise sadece melanom dışı deri kanseri saptandı. Melanom dışı deri kanseri ve AK görülen hastaların birinde ayrıca melanom saptandı. Toplamda 12 bazal hücreli karsinom (BHK), 12 skuamöz hücreli karsinom (SHK) ve 1 adet melanom tanısı konuldu. En sık görülen BHK tipi, yüzeyel tipti ve bunu nodüler tip takip etti. Melanom dışı deri kanserlerinin en sık yerleştiği bölge yüz olup bunu saçlı deri, boyun ve üst ekstremite ekstansör yüzeyleri izledi. Sonuç: Bu geniş serinin sonuçları, UV ilişkili deri maligniteleri ve HÜ tedavisi ilişkisi olasılığını güçlendirmektedir. Daha önceki bazı yayınlardan farklı olarak SHK ve BHK aynı insidansta görülmüş, BHK’nin farklı tiplerine rastlanabileceği saptanmıştır. Birçok hastada birden fazla malign deri tümörü olduğu göz önünde bulundurulduğunda HÜ tedavisi alan tüm hastalarda bu tümörlerin oluşumunu kolaylaştıran diğer bir faktör olan güneş ışığına karşı koruyucu önlemlere uyulmasının sağlanmasının ve uzun dönem takibin ihmal edilmemesinin önemi ortaya çıkmaktadır.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Ferrari A, Carobbio A, Masciulli A, et al.: Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. Haematologica 2019;104:2391-9.
- 2. Algiraigri AH, Kassam A: Hydroxyurea for hemoglobin E/β-thalassemia: a systematic review and meta-analysis. Int J Hematol 2017;106:748-56.
- 3. Algiraigri AH, Wright NAM, Paolucci EO, Kassam A: Hydroxyurea for lifelong transfusion-dependent β-thalassemia: a meta-analysis. Pediatr Hematol Oncol 2017;34:435-48.
- 4. Vick L, Potts M, Jaskowiak M, Gibson RW: Hydroxyurea adherence strategies for persons with sickle cell disease: A systematic review. J Health Care Poor Underserved 2021;32:99-118.
- 5. Renneville A, Patnaik MM, Chan O, Padron E, Solary E: Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia. Leukemia 2021;35:2739-51.
- 6. Ruzzon E, Randi ML, Tezza F, Luzzatto G, Scandellari R, Fabris F: Leg ulcers in elderly on hydroxyurea: a single center experience in Ph- myeloproliferative disorders and review of literature. Aging Clin Exp Res 2006;18:187-90.
- 7. Wiechert A, Reinhard G, Tüting T, Uerlich M, Bieber T, Wenzel J: Multiple kutane neoplasien nach therapie mit hydroxyurea [multiple skin cancers in a patient treated with hydroxyurea]. Hautarzt 2009;60:651-4.
- 8. Sanchez-Palacios C, Guitart J: Hydroxyurea-associated squamous dysplasia. J Am Acad Dermatol 2004;51:293-300.
- 9. Cantisani C, Kiss N, Naqeshbandi AF, et al.: Nonmelanoma skin cancer associated with hydroxyurea treatment: overview of the literature and our own experience. Dermatol Ther 2019;32:e13043.
- 10. Bulte CA, Hoegler KM, Kutlu Ö, Khachemoune A: Hydroxyurea: a reappraisal of its cutaneous side effects and their management. Int J Dermatol 2021;60:810-7.
- 11. Lacouture M, Sibaud V: Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol 2018;19:31-9.
- 12. Wu JH, Cohen DN, Rady PL, Tyring SK: BRAF inhibitor-associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management. Br J Dermatol 2017;177:914-23.
- 13. Barbui T, Ghirardi A, Masciulli A, et al.: Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Leukemia 2019;33:1996-2005.
- 14. Brabrand M, Frederiksen H: Risks of solid and lymphoid malignancies in patients with myeloproliferative neoplasms: clinical implications. Cancers (Basel) 2020;12:3061.
- 15. Gavini DR, Salvi DJ, Shah PH,Uma D, Lee JH, Hamid P: Non-melanoma skin cancers in patients on hydroxyurea for Philadelphia chromosome-negative myeloproliferative neoplasms: A systematic review. Cureus 2021;13:e16978.
- 16. Gómez M, Guillem V, Pereira A, et al.: Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera. Eur J Haematol 2016;96:285-90.
- 17. Harrison CN, Vannucchi AM, Kiladjian JJ, et al.: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 2016;30:1701-7.
- 18. Verstovsek S, Vannucchi AM, Griesshammer M, et al.: Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica 2016;101:821-9.
- 19. Polverelli N, Elli EM, Abruzzese E, et al.: Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol 2021;193:356-68.
- 20. Mora B, Rumi E, Guglielmelli P, et al.: Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 2233 patients. Cancer Med 2019;8:4089-92.
- 21. Blechman AB, Cabell CE, Weinberger CH, et al.: Aggressive skin cancers occurring in patients treated with the Janus kinase inhibitor ruxolitinib. J Drugs Dermatol 2017;16:508-11.
- 22. Aboul-Fettouh N, Nijhawan RI: Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib. JAAD Case Rep 2018;4:455-7.
- 23. Yarbro JW: Mechanism of action of hydroxyurea. Semin Oncol 1992;19(Suppl 9):1-10.
- 24. Saraceno R, Teoli M, Chimenti S: Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject. Clin Ther 2008;30:1324-9.
- 25. Disdier P, Harle JR, Grob JJ, Weiller-Merli C, Magalon G, Weiller PJ: Rapid development of multiple squamous-cell carcinomas during chronic granulocytic leukemia. Dermatologica 1991;183:47-8.
- 26. SchleussingerTM, Dyall-Smith D, Field LM: Hydroxyurea-associated squamous dysplasia in a monozygotic twin. J Am Acad Dermatol 2011;65:679-80.
- 27. Vassallo C, Passamonti F, Merante S, et al.: Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. Clin Exp Dermatol 2001;26:141-8.
- 28. Malato A, Rossi E, Palumbo GA, Guglielmelli P, Pugliese N: Drugrelated cutaneous adverse events in Philadelphia chromosome-negative myeloproliferative neoplasms: a literature review. Int J Mol Sci 2020;21:3900.
- 29. Antonioli E, Guglielmelli P, Pieri L, et al.: Hydroxyurea-related toxicity in 3,411 patients with Ph’-negative MPN. Am J Hematol 2012;87:552-4.
- 30. Salmon-Ehr V, Leborgne G, Vilque JP, Potron G, Bernard P: Secondary cutaneous effects of hydroxyurea: prospective study of 26 patients from a dermatologic consultation. Rev Med Interne 2000;21:30-4.
- 31. Kissova J, Ovesna P, Penka M, Bulikova A, Kiss I: Second malignancies in Philadelphia-negative myeloproliferative neoplasms-single-center experience. Anticancer Res 2014;34:2489-96.
- 32. Radić J, Batinac T, Hadžisejdić I, Načinović-Duletić A, Valković T, Jonjić N: Concurrent basal cell and squamous cell carcinomas associated with hydroxyurea therapy. Acta Dermatovenerol Croat 2011;19:183-6.
- 33. García-Martínez FJ, García-Gavín J, Alvarez-Pérez A, Alonso-González J, Ginarte M, Toribio J: Scleroderma-like syndrome due to hydroxyurea. Clin Exp Dermatol 2012;37:755-8.
- 34. Stone T, Berger A, Blumberg S, et al.: A multidisciplinary team approach to hydroxyurea-associated chronic wound with squamous cell carcinoma. Int Wound J 2012;9:324-9.
- 35. De Benedittis M, Petruzzi M, Giardina C, Lo Muzio L, Favia G, Serpico R: Oral squamous cell carcinoma during long-term treatment with hydroxyurea. Clin Exp Dermatol 2004;29:605-7.
- 36. Aste N, Fumo G, Biggio P: Multiple squamous epitheliomas during long-term treatment with hydroxyurea. J Eur Acad Dermatol Venereol 2001;15:89-90.
- 37. Neill B, Ryser T, Neill J, Aires D, Rajpara A: A patient case highlighting the myriad of cutaneous adverse effects of prolonged use of hydroxyurea. Dermatol Online J 2017;23:13030/qt8h64503t.
- 38. De Simone C, Guerriero C, Guidi B, Rotoli M, Venier A, Tartaglione R: Multiple squamous cell carcinomas of the skin during long-term treatment with hydroxyurea. Eur J Dermatol 1998;8:114-5.
- 39. Pamuk GE, Turgut B, Vural O, Demir M, Tek M, Altaner S: Metastatic squamous cell carcinoma of the skin in chronic myeloid leukaemia: complication of hydroxyurea therapy. Clin Lab Haematol 2003;5:329-31.
- 40. Verner E, Forsyth C, Grigg A: Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea. Leuk Lymphoma 2014;55:1139-43.
- 41. Saito A, Fujisawa Y, Maruyama H, et al.: Subungual melanoma complicated by hydroxyurea-induced melanonychia with non-melanoma Hutchinson’s sign. Eur J Dermatol 2018;28:559-61.
- 42. John AM, Schwartz RA: Muir-Torre syndrome (MTS): an update and approach to diagnosis and management. J Am Acad Dermatol 2016;74:558-66.
- 43. Ponti G, Ponz de Leon M: Muir-Torre syndrome. Lancet Oncol 2005;6:980-7.
- 44. Estève E, Georgescu V, Heitzmann P, Martin L: Multiple skin and mouth squamous cell carcinomas related to long-term treatment with hydroxyurea. Ann Dermatol Venereol 2001;128:919-21.
- 45. Best PJ, Petitt RM: Multiple skin cancers associated with hydroxyurea therapy. Mayo Clin Proc 1998;73:961-3.
| APA | Baykal C, Bölük K, Kılıç Sayar S, öztürk sarı ş, Mahmudov A, BÜYÜKBABANI N (2022). Precancerous skin lesions and malignant skin tumors associated with hydroxyurea treatment: Evaluation of a large series and review of the literature. , 159 - 165. 10.4274/turkderm.galenos.2022.91489 |
| Chicago | Baykal Can,Bölük Kübra Nursel,Kılıç Sayar Sıla,öztürk sarı şule,Mahmudov Amid,BÜYÜKBABANI NESIMI Precancerous skin lesions and malignant skin tumors associated with hydroxyurea treatment: Evaluation of a large series and review of the literature. (2022): 159 - 165. 10.4274/turkderm.galenos.2022.91489 |
| MLA | Baykal Can,Bölük Kübra Nursel,Kılıç Sayar Sıla,öztürk sarı şule,Mahmudov Amid,BÜYÜKBABANI NESIMI Precancerous skin lesions and malignant skin tumors associated with hydroxyurea treatment: Evaluation of a large series and review of the literature. , 2022, ss.159 - 165. 10.4274/turkderm.galenos.2022.91489 |
| AMA | Baykal C,Bölük K,Kılıç Sayar S,öztürk sarı ş,Mahmudov A,BÜYÜKBABANI N Precancerous skin lesions and malignant skin tumors associated with hydroxyurea treatment: Evaluation of a large series and review of the literature. . 2022; 159 - 165. 10.4274/turkderm.galenos.2022.91489 |
| Vancouver | Baykal C,Bölük K,Kılıç Sayar S,öztürk sarı ş,Mahmudov A,BÜYÜKBABANI N Precancerous skin lesions and malignant skin tumors associated with hydroxyurea treatment: Evaluation of a large series and review of the literature. . 2022; 159 - 165. 10.4274/turkderm.galenos.2022.91489 |
| IEEE | Baykal C,Bölük K,Kılıç Sayar S,öztürk sarı ş,Mahmudov A,BÜYÜKBABANI N "Precancerous skin lesions and malignant skin tumors associated with hydroxyurea treatment: Evaluation of a large series and review of the literature." , ss.159 - 165, 2022. 10.4274/turkderm.galenos.2022.91489 |
| ISNAD | Baykal, Can vd. "Precancerous skin lesions and malignant skin tumors associated with hydroxyurea treatment: Evaluation of a large series and review of the literature". (2022), 159-165. https://doi.org/10.4274/turkderm.galenos.2022.91489 |
| APA | Baykal C, Bölük K, Kılıç Sayar S, öztürk sarı ş, Mahmudov A, BÜYÜKBABANI N (2022). Precancerous skin lesions and malignant skin tumors associated with hydroxyurea treatment: Evaluation of a large series and review of the literature. Türkderm Türk deri hastalıkları ve frengi arşivi, 56(4), 159 - 165. 10.4274/turkderm.galenos.2022.91489 |
| Chicago | Baykal Can,Bölük Kübra Nursel,Kılıç Sayar Sıla,öztürk sarı şule,Mahmudov Amid,BÜYÜKBABANI NESIMI Precancerous skin lesions and malignant skin tumors associated with hydroxyurea treatment: Evaluation of a large series and review of the literature. Türkderm Türk deri hastalıkları ve frengi arşivi 56, no.4 (2022): 159 - 165. 10.4274/turkderm.galenos.2022.91489 |
| MLA | Baykal Can,Bölük Kübra Nursel,Kılıç Sayar Sıla,öztürk sarı şule,Mahmudov Amid,BÜYÜKBABANI NESIMI Precancerous skin lesions and malignant skin tumors associated with hydroxyurea treatment: Evaluation of a large series and review of the literature. Türkderm Türk deri hastalıkları ve frengi arşivi, vol.56, no.4, 2022, ss.159 - 165. 10.4274/turkderm.galenos.2022.91489 |
| AMA | Baykal C,Bölük K,Kılıç Sayar S,öztürk sarı ş,Mahmudov A,BÜYÜKBABANI N Precancerous skin lesions and malignant skin tumors associated with hydroxyurea treatment: Evaluation of a large series and review of the literature. Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(4): 159 - 165. 10.4274/turkderm.galenos.2022.91489 |
| Vancouver | Baykal C,Bölük K,Kılıç Sayar S,öztürk sarı ş,Mahmudov A,BÜYÜKBABANI N Precancerous skin lesions and malignant skin tumors associated with hydroxyurea treatment: Evaluation of a large series and review of the literature. Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(4): 159 - 165. 10.4274/turkderm.galenos.2022.91489 |
| IEEE | Baykal C,Bölük K,Kılıç Sayar S,öztürk sarı ş,Mahmudov A,BÜYÜKBABANI N "Precancerous skin lesions and malignant skin tumors associated with hydroxyurea treatment: Evaluation of a large series and review of the literature." Türkderm Türk deri hastalıkları ve frengi arşivi, 56, ss.159 - 165, 2022. 10.4274/turkderm.galenos.2022.91489 |
| ISNAD | Baykal, Can vd. "Precancerous skin lesions and malignant skin tumors associated with hydroxyurea treatment: Evaluation of a large series and review of the literature". Türkderm Türk deri hastalıkları ve frengi arşivi 56/4 (2022), 159-165. https://doi.org/10.4274/turkderm.galenos.2022.91489 |
